Erratum: Clinicopathological Features and Therapeutic Responses of Chinese Patients with Advanced Lung Adenocarcinoma Harboring an Anaplastic Lymphoma Kinase Rearrangement

<b><i>Background:</i></b> Presence of anaplastic lymphoma kinase (<i>ALK</i>) rearrangement is an indication for crizotinib in the treatment of patients with advanced or metastatic lung adenocarcinoma. Here, we sought to elucidate the association between clinicopathological features and <i>ALK</i> rearrangement status in Chinese patients with advanced lung adenocarcinoma harboring an <i>ALK</i> rearrangement. <b><i>Patients and Methods:</i></b><i>ALK</i> rearrangement status was determined using immunohistochemistry (IHC) in tumor tissues from 120 patients with advanced lung adenocarcinoma, and further assessed by fluorescence in situ hybridization (FISH) assay. The associations between <i>ALK</i> rearrangement status and clinicopathological features were analyzed. <b><i>Results:</i></b> According to IHC testing, the <i>ALK</i>-positive rate among the advanced lung adenocarcinoma patients was 6.67% (8/120). FISH validation found 5 patients with <i>ALK</i> rearrangement among the 8 IHC-positive cases. No significant difference was observed regarding age, sex, or smoking status between FISH-positive and -negative patients (p > 0.05). None of the 5 FISH-positive patients benefited from first-line chemotherapy. <b><i>Conclusion:</i></b> IHC can be used as a reliable method for <i>ALK</i> rearrangement screening in patients with lung adenocarcinoma, but further FISH validation is imperative. Presence of <i>ALK</i> rearrangement predicts a more aggressive biological behavior of the tumor and might be indicative of poor response to chemotherapy.